DEF 14A: Upstream Bio, Inc. Announces 2025 Annual Meeting of Stockholders

Upstream Bio, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 10, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• Upstream Bio, Inc. is holding its 2025 Annual Meeting of Stockholders virtually on June 10, 2025, at 8:00 a.m. Eastern Time.
• Stockholders of record as of April 14, 2025, are entitled to vote.
• The meeting will address the election of two class I directors, each to serve until the 2028 annual meeting.
• The meeting will also address the ratification of PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board of directors recommends voting FOR the election of the director nominees and FOR the ratification of the accounting firm appointment.
• The company is providing proxy materials online, mailing a Notice of Internet Availability of Proxy Materials on or about April 17, 2025.
• Stockholders can vote online, by telephone, by mail, or during the virtual Annual Meeting.
• The board of directors consists of seven members divided into three classes with staggered three-year terms.
• The board has determined that all members of the board of directors are independent directors, including for purposes of the rules of Nasdaq and the SEC, except for Dr. Sutherland, due to his role as the Chief Executive Officer of the Company.
• The company has established an audit committee, a compensation committee and a nominating and corporate governance committee.
• The company has adopted an insider trading policy which governs transactions in our securities by the Company and its directors, officers, employees, and consultants.
• The company has adopted a Rule 10b5-1 trading plan policy, which permits our officers, directors, employees and certain other persons to enter into trading plans complying with Rule 10b5-1 under the Exchange Act.
• The company maintains a compensation recovery policy (the clawback policy).
• The company has adopted a written code of business conduct and ethics that applies to our directors, officers and employees.
• The company has adopted a written related person transaction policy providing for the review and oversight of all transactions involving over $120,000 in which the Company is a participant and a related person has a direct or indirect interest.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The information is presented in a factual and objective manner, with no overt positive or negative sentiment expressed. The document's purpose is to inform stockholders and solicit their votes on routine corporate governance matters.

Positives

• The company is adhering to good corporate governance practices by seeking stockholder ratification of the independent accounting firm appointment.
• The board of directors is comprised of mostly independent directors.
• The company has a compensation recovery policy (clawback policy) in place.
• The company has a written code of business conduct and ethics that applies to our directors, officers and employees.
• The company has a written related person transaction policy providing for the review and oversight of all transactions involving over $120,000 in which the Company is a participant and a related person has a direct or indirect interest.

Risks

• The proxy statement notes that directors may be removed only for cause by the affirmative vote of the holders of not less than two-thirds (2/3) of the voting power of the outstanding shares then entitled to vote at an election of directors, which could entrench management.
• The company faces risks inherent to every business, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction and intellectual property.

Future Outlook

The company does not provide specific forward-looking financial guidance in this proxy statement.

Industry Context

This is a standard proxy statement for a publicly traded biopharmaceutical company, outlining routine corporate governance matters such as director elections and auditor ratification. The details regarding related party transactions are typical for companies with significant venture capital backing.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity grants, is generally in line with industry standards for similarly sized biopharmaceutical companies.
• The company's corporate governance policies, such as the code of business conduct and ethics and the related person transaction policy, are consistent with best practices for publicly traded companies.
• The fees paid to the independent registered public accounting firm are comparable to those paid by other biopharmaceutical companies of similar size and complexity.

Management Changes

Corporate Governance

Related Party Transactions

• Since January 1, 2023, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of our total asset amounts at December 31, 2023 and 2024) and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.

Stakeholder Impact

• The election of directors and ratification of the accounting firm are important for maintaining corporate governance and accountability to stockholders.
• The executive compensation arrangements and severance plan impact the financial well-being of the company's executives.
• The related party transactions policy aims to ensure fair dealings and protect the interests of all stockholders.

Next Steps

• Stockholders should review the proxy materials and vote their shares.
• The company will hold the Annual Meeting on June 10, 2025.
• The company will file a Form 8-K to announce the final voting results after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Director Election, PricewaterhouseCoopers, Corporate Governance, Executive Compensation, Upstream Bio